Hieu Tran
Family · New Orleans, LANPI 1730668799
Payments from drug & device makers
Across 171 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$659
- Novo Nordisk$387
- Merck$266
- Boehringer Ingelheim$263
- Lilly USA, LLC$213
- Sanofi-aventis U.S. LLC$148
- plus $896 from 19 others
What the payments were for
- Food & beverage$2,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $659 |
| Novo Nordisk | 26 | $387 |
| Merck | 18 | $266 |
| Boehringer Ingelheim | 14 | $263 |
| Lilly USA, LLC | 13 | $213 |
| Sanofi-aventis U.S. LLC | 8 | $148 |
| Amgen | 8 | $147 |
| AbbVie | 7 | $132 |
| Esperion Therapeutics, Inc. | 6 | $99 |
| Viiv Healthcare Company | 5 | $98 |
| Amneal Pharmaceuticals LLC | 7 | $94 |
| Amryt Pharma Holdings Ltd | 2 | $42 |
| Dexcom, Inc. | 2 | $39 |
| Bayer | 2 | $31 |
| Theratechnologies Inc. | 1 | $30 |
| IBSA Pharma Inc. | 1 | $24 |
| GSK | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Mannkind Corporation | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yeztugo$125
How this compares
$2,831 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $37,639 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 14 | $1,333 |
| Metformin Hcl ErMetformin Hcl | 24 | $363 |
| Atorvastatin Calcium | 42 | $181 |
| Fluticasone Propionate | 11 | $164 |
| Amlodipine Besylate | 38 | $160 |
| Losartan Potassium | 18 | $75 |
| Lisinopril | 16 | $52 |
| Meloxicam | 12 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $659 | $37,63917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Robert ByramNew Orleans$49K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.